Atea Pharmaceuticals. has been granted a patent for a hemi-sulfate salt aimed at treating hepatitis C. The patent includes details on pharmaceutical compositions and a process for preparing the compound, which involves dissolving a precursor compound in an organic solvent. GlobalData’s report on Atea Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Atea Pharmaceuticals, Recombinant AAV gene therapy was a key innovation area identified from patents. Atea Pharmaceuticals's grant share as of June 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
Hemi-sulfate salt for treating hepatitis c infection
The patent US12006340B2 outlines a detailed process for preparing Compound 2 from Compound 1, involving several specific steps and conditions. The initial step requires dissolving Compound 1 in an organic solvent, with various options provided, including acetone, ethyl acetate, and methanol. The process specifies a critical ratio of sulfuric acid (H2SO4) to Compound 1, approximately 0.5 to 1, and includes a subsequent step where the H2SO4 is mixed with a solvent, with preferred combinations such as H2SO4/methanol. The mixture is to be cooled to a temperature between 0-10°C before being added to the dissolved Compound 1.
Further steps in the process include the precipitation of Compound 2, which is then washed with a mixture of organic solvents, with specific combinations like methanol/acetone being highlighted. The final steps involve drying Compound 2 in a vacuum, with temperature conditions specified between 55°C to 60°C. The claims also emphasize the use of specific solvents throughout the process, ensuring a controlled environment for the synthesis of Compound 2. Overall, the patent provides a comprehensive methodology for the preparation of Compound 2, detailing the necessary conditions and materials involved.
To know more about GlobalData’s detailed insights on Atea Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
